Dr. Chiang on Toxicities with Ipilimumab Plus Nivolumab in Small Cell Lung Cancer

September 1, 2017
Anne Chiang, MD, PhD, Yale School of Medicine Smilow Cancer Hospital

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses the toxicities with ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer (SCLC).

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses the toxicities with ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer (SCLC).

The toxicities are similar to what is expected with each drug alone, explains Chiang. Around 70% of patients had treatment-related adverse events (AEs), but many of the toxicities could be easily managed. However, 10% of patients discontinued treatment due to the AEs.


x